Abstract：
BACKGROUND: Levodopa is used to treat hyperkinetic movements in children with dopa-responsive dystonia. However, levodopa may also be helpful in treating other forms of dystonia when used beyond a brief trial period.
METHODS: We performed a retrospective review of all children referred to our institution for evaluation of generalized dystonia and subsequently treated with carbidopa-levodopa. Motor function was assessed using video recordings and examination notes, quantified with the Burke-Fahn-Marsden Dystonia Rating Scale.
RESULTS: Long-term treatment with carbidopa-levodopa moderately improved motor function, whereas short-term use did not. Carbidopa-levodopa was well tolerated without untoward effects.
CONCLUSIONS: Dystonia is a significant cause of disability with limited effective treatment options. Published work is restricted but generally supports the findings of this review. A well-controlled study to examine the utility of carbidopa-levodopa treatment for dystonia is needed.
METHODS: We performed a retrospective review of all children referred to our institution for evaluation of generalized dystonia and subsequently treated with carbidopa-levodopa. Motor function was assessed using video recordings and examination notes, quantified with the Burke-Fahn-Marsden Dystonia Rating Scale.
RESULTS: Long-term treatment with carbidopa-levodopa moderately improved motor function, whereas short-term use did not. Carbidopa-levodopa was well tolerated without untoward effects.
CONCLUSIONS: Dystonia is a significant cause of disability with limited effective treatment options. Published work is restricted but generally supports the findings of this review. A well-controlled study to examine the utility of carbidopa-levodopa treatment for dystonia is needed.
摘要：
背景：左旋多巴用于治疗多巴反应性肌张力障碍儿童的运动过度运动。然而,左旋多巴在治疗其他形式的肌张力障碍时也可能有帮助。
方法：我们对所有转诊到我们机构评估全身性肌张力障碍并随后接受卡比多巴-左旋多巴治疗的儿童进行了回顾性研究。使用视频记录和检查笔记评估运动功能，用伯克-法恩-马斯登肌张力障碍量表量化。
结果：卡比多巴-左旋多巴长期治疗可适度改善运动功能，而短期使用没有。卡比多巴-左旋多巴耐受性良好，无不良反应。
结论：肌张力障碍是导致残疾的重要原因，有效的治疗选择有限。已发表的工作受到限制，但总体上支持本审查的结果。需要进行良好的对照研究，以检查卡比多巴-左旋多巴治疗肌张力障碍的效用。
方法：我们对所有转诊到我们机构评估全身性肌张力障碍并随后接受卡比多巴-左旋多巴治疗的儿童进行了回顾性研究。使用视频记录和检查笔记评估运动功能，用伯克-法恩-马斯登肌张力障碍量表量化。
结果：卡比多巴-左旋多巴长期治疗可适度改善运动功能，而短期使用没有。卡比多巴-左旋多巴耐受性良好，无不良反应。
结论：肌张力障碍是导致残疾的重要原因，有效的治疗选择有限。已发表的工作受到限制，但总体上支持本审查的结果。需要进行良好的对照研究，以检查卡比多巴-左旋多巴治疗肌张力障碍的效用。
